48 hasil untuk "Francesca Gay"
Menampilkan 1–20 · 1,20 detik · RSS
-
Artikel Jurnal
Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
In the biology of multiple myeloma (MM), immune dysregulation has emerged as a critical component for novel therapeutic strategies. This dysfunction is due to a reduced antigen presentation, a reduced effector cell ability and a loss of reactive T cells against myeloma, together with a bone marrow…
-
Artikel Jurnal
Moving Toward Continuous Therapy in Multiple Myeloma
The introduction of novel agents, characterized by favorable toxicity profiles and higher manageability compared to conventional drugs employed in the past, has considerably changed the treatment paradigm for multiple myeloma. Continuous therapy currently represents the standard approach for…
-
Artikel Jurnal
Current positioning and future development of belantamab mafodotin and other antibody-drug conjugates to treat multiple myeloma
The treatment of Multiple myeloma (MM) has been revolutionized by the advent of immunotherapies. Monoclonal antibodies targeting specific markers greatly contributed to patients’ outcome improvement. Antibodies can be conjugated with a toxic payload to exert anti-tumor efficacy (antibody–drug…
-
Artikel Jurnal
Clinical outcomes associated with anti-CD38-based retreatment in relapsed/refractory multiple myeloma: a systematic literature review
IntroductionAnti-CD38-based therapy has become a backbone regimen for the treatment of multiple myeloma (MM), approved in first-, second-, and third-line settings. The effectiveness of anti-CD38-based retreatment after an initial relapse on previous anti-CD38-based therapy is unclear. Here we…
-
Artikel Jurnal
Peripheral monoclonal plasmacytosis in infective endocarditis: a tangled web
Not available.
-
Artikel Jurnal Teks lengkap
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry
Multiple myeloma is a haematological malignancy typically characterised by neoplastic plasma cell infiltration of the bone marrow. Treatment for multiple myeloma consists of multi-line chemotherapy with or without autologous stem cell transplantation and has been rapidly evolving in recent years…
-
Artikel Jurnal
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Abstract Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE)…
-
Artikel Jurnal
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
We used a modified Delphi approach to establish areas of consensus and nonconsensus regarding the utility of determining measurable residual disease (MRD) to assess multiple myeloma (MM) treatment response, which may inform disease management and design of future clinical trials. This modified…
-
Artikel Jurnal
Effects of Carfilzomib Therapy on Left Ventricular Function in Multiple Myeloma Patients
Background: Carfilzomib improves the prognosis of multiple myeloma (MM) patients but significantly increases cardiovascular toxicity. The timing and effect of Carfilzomib therapy on the left ventricular function is still under investigation. We sought to assess the echocardiographic systo-diastolic…
-
Artikel Jurnal
Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies
Multiple myeloma is a plasma cell disorder characterized by malignant plasma cell infiltration in the bone marrow, serum and/or urine monoclonal protein and organ damage. The aim of this study was to investigate the impact of chromosome 1 abnormalities in a group of elderly patients (>65 years)…
-
Artikel Jurnal
Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial
Background Defibrotide is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects. In SCID/NOD mice, defibrotide showed activity in human myeloma xenografts. This phase I/II study was conducted to identify the most appropriate dose of defibrotide in…
-
Artikel Jurnal Teks lengkap
MDM2 Drives Proteasome Inhibitor Resistance and Represents a TP53-Independent Therapeutic Vulnerability in Multiple Myeloma
Proteasome inhibitors (PIs) are central to multiple myeloma (MM) therapy; however, resistance remains a major clinical challenge, particularly in relapsed/refractory disease. To identify functional mediators of carfilzomib (CFZ) resistance, we performed complementary gain-of-function CRISPR…
-
Artikel Jurnal
Bedaquiline amplifies proteasome inhibitor efficacy and overcomes resistance in multiple myeloma
Proteasome inhibitors (PIs) are cornerstone therapies for multiple myeloma (MM), yet resistance remains a major barrier to durable responses. To identify druggable vulnerabilities that enhance PI efficacy, we performed a small-molecule chemical screen in the presence of carfilzomib (CFZ). We…